Orphazyme is in dialog with a number of potential suitors in search of rescue
Biotech company Orphazyme is in need of a lifeline, and its deputy chair, Bo Jesper Hansen, is in talks with five to ten potential buyers and investors as a part of current restructuring plans.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
On Thursday, Orphazyme released its restructuring plan, stating that potential investors and buyers had already been identified and contacted.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme's creditors left without real options
For subscribers
